Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24801833 | 0.91 | NPC1 (0.67) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL11674120 | 0.90 | SMN1; SMN2 (0.89) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL13882293 | 0.88 | SMN1; SMN2 (0.85) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL11964433 | 0.86 | NPC1 (0.59) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL16675211 | 0.86 | SMN1; SMN2 (0.82) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL13143834 | 0.84 | NPC1 (0.69) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL9341650 | 0.83 | NPC1 (0.61) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL12634931 | 0.83 | NPC1 (0.83) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL13393581 | 0.81 | TRPM8 (0.60) | HPGDSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL1186494 | 0.81 | GUSB (0.51) | HPGDSMN1; SMN2NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-2861789-B1 | FLAME RESISTANT SPUN STAPLE YARNS MADE FROM BLENDS OF FIBERS DERIVED FROM SULFONATED NAPHTHALENE POLYOXADIAZOLE POLYMERS | DUPONT SAFETY & CONSTRUCTION INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| EP-3299518-A1 | FIBRE PAPER COMPRISING POD AND PREPARATION METHOD THEREFOR | Jiangsu Pod New Material Co., Ltd (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-20080085992-A1 | Polymers and fibers formed therefrom | DUPONT SAFETY & CONSTRUCTION, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085992-A1 | Polymers and fibers formed therefrom | DUPONT SAFETY & CONSTRUCTION, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080014440-A1 | Polyoxadiazole composite fibers | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080014440-A1 | Polyoxadiazole composite fibers | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-01-17 | — | — | US | disclosed |
| WO-2008008185-A2 | POLYOXADIAZOLE COMPOSITE FIBERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070065601-A1 | Optical film, and polarizing plate and liquid crystal display device using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | HPGD 2842/4885SMN1; SMN2 813/4885NPC1 2293/4885 |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | HPGD 696/4885SMN1; SMN2 7/4885NPC1 3175/4885 |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | HPGD 644/4885SMN1; SMN2 1094/4885NPC1 3602/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | HPGD 1603/4885SMN1; SMN2 1340/4885NPC1 1302/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | HPGD 696/4885SMN1; SMN2 7/4885NPC1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.